Author: Mazilu, Laura; Katsiki, Niki; Nikolouzakis, Taxiarchis Konstantinos; Aslanidis, Minas I.; Lazopoulos, George; Kouretas, Dimitrios; Tsatsakis, Aristidis; Suceveanu, Andra-Iulia; Stoian, Anca-Pantea; Parepa, Irinel-Raluca; Voinea, Felix; Suceveanu, Adrian Paul; Arsene, Andreea Letiția; Velescu, Bruno Ștefan; Vesa, Cosmin; Nitipir, Cornelia
Title: Thrombosis and Haemostasis challenges in COVID-19 – Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review Cord-id: kvprwlsz Document date: 2021_1_6
ID: kvprwlsz
Snippet: The coronavirus disease (COVID)-19 pandemic is a major challenge for the health systems worldwide. Acute respiratory distress syndrome (ARDS), is one of the most common complications of the COVID-19 infection. The activation of the coagulation system plays an important role in the pathogenesis of ARDS. The development of lung coagulopathy involves thrombin generation and fibrinolysis inhibition. Unfractionated heparin and its recently introduced counterpart low molecular weight heparin (LMWH), a
Document: The coronavirus disease (COVID)-19 pandemic is a major challenge for the health systems worldwide. Acute respiratory distress syndrome (ARDS), is one of the most common complications of the COVID-19 infection. The activation of the coagulation system plays an important role in the pathogenesis of ARDS. The development of lung coagulopathy involves thrombin generation and fibrinolysis inhibition. Unfractionated heparin and its recently introduced counterpart low molecular weight heparin (LMWH), are widely used anticoagulants with a variety of clinical indications allowing for limited and manageable physio-toxicologic side effects while the use of protamine sulfate, heparin's effective antidote, has made their use even safer. Tissue-type plasminogen activator (tPA) is approved as intravenous thrombolytic treatment. The present narrative review discusses the use of heparin and tPA in the treatment of COVID-19-induced ARDS and their related potential physio-toxicologic side effects. The article is a quick review of articles on anticoagulation in COVID infection and the potential toxicologic reactions associated with these drugs.
Search related documents:
Co phrase search for related documents- acute phase and low molecular: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and low molecular lmwh weight heparin: 1, 2
- acute phase and lung diffusion: 1, 2, 3
- acute phase and lung epithelium: 1, 2
- acute phase and lung failure: 1, 2, 3
- acute phase and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute phase and lung function improve: 1
- acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- acute phase and lung limit: 1
- acute phase and lung parenchyma: 1, 2, 3, 4
- acute phase and lung sample: 1
- acute phase protein and lung injury: 1, 2, 3
- acute phase protein and lung parenchyma: 1
- acute pulmonary injury and lung epithelium: 1
- acute pulmonary injury and lung failure: 1, 2, 3, 4, 5
- acute pulmonary injury and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute pulmonary injury and lung function improve: 1
- acute pulmonary injury and lung initiate: 1
- acute pulmonary injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Co phrase search for related documents, hyperlinks ordered by date